President Barack Obama plans to meet with Democratic lawmakers in Congress to discuss how to protect his signature healthcare law from Republican efforts to dismantle it, Politico reported.
A year ago, the mosquito-borne Zika virus was only beginning to reveal itself as a threat to pregnant women and their unborn babies. Since then, U.S. officials have issued 60 travel alerts along with guidance for athletes and tourists traveling to the Olympics in Rio. They have also deployed more than 1,000 experts to Puerto Rico and elsewhere, tested more than 147,000 lab specimens, initiated 25 major studies and issued more than 230 scientific publications. And the work is not done, said Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention.
OPKO Health Inc. said its experimental drug for GHD in adults failed to provide a statistically significant benefit over a placebo in a late-stage study.
A diet rich in magnesium – found in foods like leafy greens, fish, nuts and whole grains – may help lower the risk of chronic health problems like heart disease and diabetes, a research review suggests.
2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
Innocoll received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.
Fewer people in the U.S. have celiac disease without realizing it, a new study finds.
Web-based therapy for insomnia is an effective option that could reach “previously unimaginable numbers of people,” researchers suggest.
The FDA rejected Cempra Inc.’s antibiotic for community-acquired bacterial pneumonia, citing inadequate data on the drug’s impact on liver and manufacturing issues.
Biogen finally set a price tag for its newly approved spinal atrophy drug Spinraza – the first drug ever approved for the disease – and as expected, it’s in the high six figures.